Blockchain Registration Transaction Record

Scinai Immunotherapeutics Secures $4M in Private Placement to Fuel CDMO and Immunotherapy Growth

Scinai Immunotherapeutics raises $4M in private placement to expand CDMO platform and advance immunotherapy pipeline. A.G.P. is sole placement agent.

This funding provides Scinai with critical capital to scale its CDMO operations and advance its immunotherapy pipeline, potentially accelerating revenue generation and therapeutic development. For investors, it signals confidence from an existing institutional investor and could enhance the company's growth prospects. Moreover, the expansion of CDMO services supports the broader biotech ecosystem by offering development and manufacturing capabilities, while the immunotherapy advancements may lead to novel treatments licensed from prestigious institutions like the Max Planck Society.